PURPOSE: Trastuzumab treatment is associated with occurrence of cardiac toxicity, for which monitoring of the left ventricular ejection fraction (LVEF) is indicated. The performance of the currently used monitoring protocol as defined in the summary of product characteristics (SPC) is however unknown. The objective of this analysis was to develop a model-based framework for evaluation and optimization of cardiac monitoring strategies. METHODS: The model-based framework comprised a previously developed exposure-response model for trastuzumab induced changes in LVEF, and a protocol-execution model that allowed incorporation of treatment interventions as described by a monitoring protocol. Metrics for evaluation of toxicity, dose intensity and monitoring burden were defined to allow evaluation and optimization of cardiac monitoring protocols. RESULTS: The success of a protocol-defined dose reduction was improved from 40% for the SPC-based protocol, to 79% for a scoring-based protocol, thereby decreasing the observed severity of cardiotoxicity. Including adaptation based on risk-profile allowed reduction of the mean number of LVEF measurements by 19%. CONCLUSIONS: This model-based evaluation approach enabled evaluation and optimization of cardiac monitoring protocols that would be difficult to evaluate in a clinical setting. This approach can potentially be applied for other drugs that use repeated evaluation of continuous biomarkers for toxicity.
PURPOSE:Trastuzumab treatment is associated with occurrence of cardiac toxicity, for which monitoring of the left ventricular ejection fraction (LVEF) is indicated. The performance of the currently used monitoring protocol as defined in the summary of product characteristics (SPC) is however unknown. The objective of this analysis was to develop a model-based framework for evaluation and optimization of cardiac monitoring strategies. METHODS: The model-based framework comprised a previously developed exposure-response model for trastuzumab induced changes in LVEF, and a protocol-execution model that allowed incorporation of treatment interventions as described by a monitoring protocol. Metrics for evaluation of toxicity, dose intensity and monitoring burden were defined to allow evaluation and optimization of cardiac monitoring protocols. RESULTS: The success of a protocol-defined dose reduction was improved from 40% for the SPC-based protocol, to 79% for a scoring-based protocol, thereby decreasing the observed severity of cardiotoxicity. Including adaptation based on risk-profile allowed reduction of the mean number of LVEF measurements by 19%. CONCLUSIONS: This model-based evaluation approach enabled evaluation and optimization of cardiac monitoring protocols that would be difficult to evaluate in a clinical setting. This approach can potentially be applied for other drugs that use repeated evaluation of continuous biomarkers for toxicity.
Authors: J G C van Hasselt; A H Boekhout; J H Beijnen; J H M Schellens; A D R Huitema Journal: Clin Pharmacol Ther Date: 2011-06-01 Impact factor: 6.875
Authors: Marion Procter; Thomas M Suter; Evandro de Azambuja; Urania Dafni; Veerle van Dooren; Susanne Muehlbauer; Miguel Angel Climent; Ernst Rechberger; Walter Tsang-Wu Liu; Mazakasu Toi; R Charles Coombes; David Dodwell; Olivia Pagani; Jorge Madrid; Marcia Hall; Shin-Cheh Chen; Christian Focan; Michael Muschol; Dirk J van Veldhuisen; Martine J Piccart-Gebhart Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Jonathan Walker; Navdeep Bhullar; Nazanin Fallah-Rad; Matthew Lytwyn; Mehrdad Golian; Tielan Fang; Arthur R Summers; Pawan K Singal; Ivan Barac; Iain D Kirkpatrick; Davinder S Jassal Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart Journal: Lancet Date: 2007-01-06 Impact factor: 79.321
Authors: Steven A Crone; You-Yang Zhao; Lian Fan; Yusu Gu; Susumu Minamisawa; Yang Liu; Kirk L Peterson; Ju Chen; Ronald Kahn; Gianluigi Condorelli; John Ross; Kenneth R Chien; Kuo-Fee Lee Journal: Nat Med Date: 2002-05 Impact factor: 53.440
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Mary C Pinder; Zhigang Duan; James S Goodwin; Gabriel N Hortobagyi; Sharon H Giordano Journal: J Clin Oncol Date: 2007-07-30 Impact factor: 44.544
Authors: Edith Pituskin; Mark Haykowsky; John R Mackey; Richard B Thompson; Justin Ezekowitz; Sheri Koshman; Gavin Oudit; Kelvin Chow; Joseph J Pagano; Ian Paterson Journal: BMC Cancer Date: 2011-07-27 Impact factor: 4.430
Authors: Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2013-07 Impact factor: 4.335
Authors: J G Coen van Hasselt; Anubha Gupta; Ziad Hussein; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2013-09 Impact factor: 4.335
Authors: J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema Journal: CPT Pharmacometrics Syst Pharmacol Date: 2015-06-30
Authors: Jaehee V Shim; Bryan Chun; Johan G C van Hasselt; Marc R Birtwistle; Jeffrey J Saucerman; Eric A Sobie Journal: Front Physiol Date: 2017-09-08 Impact factor: 4.566
Authors: Aurelia H M de Vries Schultink; Annelies H Boekhout; Jourik A Gietema; Artur M Burylo; Thomas P C Dorlo; J G Coen van Hasselt; Jan H M Schellens; Alwin D R Huitema Journal: J Pharmacokinet Pharmacodyn Date: 2018-02-10 Impact factor: 2.745
Authors: Yu Fu; Hadi Taghvafard; Medhat M Said; Eric I Rossman; Teresa A Collins; Stéphanie Billiald-Desquand; Derek Leishman; Piet H van der Graaf; J G Coen van Hasselt; Nelleke Snelder Journal: CPT Pharmacometrics Syst Pharmacol Date: 2022-03-18